Humana and MemberHealth both issued profit warnings tied to lower than expected earnings from their Part D plans. The reasons are very different but the impact is the same: higher premiums from two of the biggest Medicare plans in 2009. One silver lining for advocates of the program: politically, this is a good time for Medicare plans to be struggling.
Maybe Part D isn’t such a great business for insurers after all.
After two years of almost entirely good news for big Medicare drug plan sponsors, 2008 is off to a rocky...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Patient access to mental health drugs also will be challenged by the policies in the new budget reconciliation legislation.
States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.
The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.
PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.
The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.
The long-time industry executive led several drug approvals but may have a lot to learn about the intimate details of application review and the Center for Drug Evaluation and Research.
The US FDA's Psychopharmacology Advisory Committee emphasized high standards over regulatory flexibility while turning down Otsuka's brexpiprazole plus serotonin for post-traumatic stress disorder based on conflicting Phase III trials and post-hoc Phase II analyses.
